Regardless of what players, coaches, etc., say about analytics, the thing that irks me most (irrespective of how I feel about them), is that it just seems tough to be a fan on here.
For example: If you like Nathan Beaulieu, for instance, you're an idiot.
Another example: If you don't like Mathieu Perreault, you're an idiot.
Twitter is a bad place to be a fan with a differing opinion. It's just a shit show most of the time because people are so embedded in their own cause they can't see the other side.
And the irony here is that both sides are cheering for the same thing, they just see things in a different lens.
And some will say, "Well, just don't be on Twitter."
That's a shitty solution for fans who want to be a part of a community of other fans.
It's dumb to even have to point out that people just need to be kinder to one another and allow people of the same fanbase to like players one another may not agree on.
Who cares.
The insinuation that Player A is a piece of shit because his shot differential falls below 45% or his expected goals is around the same mark grows tiresome.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Mark Scheifele doesn't like analytics. Most NHLers, anecdotally it seems, don't care one way or another. They don't have to. No GM in the league is turning down Mark Scheifele because he doesn't care for analytics.
Pierre-Luc Dubois had a better answer anyway.
Hell, no player GM in the league is turning down Mark Scheifele because his analytics don't suggest good things.
I suspect the best players don't have to give a shit about them. Some people said Leon Draisaitl wasn't great because of his poor defensive numbers.
Some people suggest Kyle Connor isn't great because of his poor defensive numbers.
And then there are coaches that use different systems for analytics that we don't see.
Manitoba's vaccine supply projection is now estimating 2,277
injections per day for March, up around 600 from last week's estimates.
Current daily capacity is now at 12,499 (goal is 20,000 by April 1).
Vaccination task force technical briefing underway. Still supply scarcity. They haven't been given a confirmed date from the feds on AstraZeneca. Estimates for Pfizer/Moderna are unchanged.
Maurice not playing his hand on if the top two lines will look like they ended last night. Won't do it on a back to back, but says he's open to moving parts around.
Maurice felt there was no cost to making last night's line changes. Wants to see those lines for a while, but won't put experimentation over winning.